Project information
Urteste Spółka Akcyjna received European Union funding for the PANURI project, a pancreatic cancer test based on enzymatic methods. The project also includes international patent protection for other urine-based cancer tests.
urteste.euCrawled Nov 19, 2026
Urteste Spółka Akcyjna received European Union funding for the PANURI project, a pancreatic cancer test based on enzymatic methods. The project also includes international patent protection for other urine-based cancer tests.
Urteste develops urine-based cancer detection tests through clinical trials. The company’s research and diagnostic potential library support the creation of additional tests.
The page lists recent news and events related to Urteste S.A., including webinars, financial announcements, and media coverage.
The company’s priority project is PANURI, a pancreatic urine cancer test that demonstrated high sensitivity and specificity in a proof-of-concept study. It is now conducting a multicenter clinical performance study to validate the technology.
The management board includes Christian Pangratz, an international manager with over 25 years of experience in biotechnology, specialty pharmaceuticals, and medical technology.
Christian Pangratz, Chief Executive Officer, has over 25 years of experience in biotechnology, specialty pharmaceuticals, and medical technology.
The page lists reports published by the company, including dates and times.
Urteste specializes in developing technology for early detection of cancer using enzyme activity measured in urine.
The page lists Urteste S.A. shareholders, their share counts, and voting percentages as of October 28, 2026.
The page details the extraordinary shareholders meeting of Urteste S.A., held on October 28, 2026, including resolutions, shareholder lists, and voting forms.
Urteste focuses on innovative projects to develop and commercialize in vitro medical products, particularly cancer diagnostics.
Urteste is developing the first method to detect multiple cancers from a single urine sample, enabling earlier diagnosis and more effective treatment.
Urteste is developing the first method to detect multiple cancers from a single urine sample, which could improve survival rates through earlier detection.
Urteste appoints Christian Pangratz as its new CEO, effective September 1, 2026. Pangratz joins with over 25 years of experience in the life sciences sector and a proven background in mergers and acquisitions. The company expands its leadership team to drive strategic growth initiatives.
Urteste releases the first peer-reviewed study validating its **Panuri test**, a diagnostic tool for **pancreatic cancer**. The paper details analytical validation methods and findings, marking a milestone in clinical testing for early detection. The company’s technology aims to improve diagnostic accuracy in pancreatic cancer screening.
Urteste secures a U.S. patent for its Panuri Test, a diagnostic tool. The patent covers the technology’s unique method for detecting specific biomarkers. The company now holds exclusive rights to commercialize the test in the United States.
Urteste has enrolled the first patient in its **Panuri test** clinical study. The trial evaluates a diagnostic test for an unspecified condition, marking a key milestone in advancing its medical technology. This development follows Urteste’s focus on precision diagnostics and clinical validation.
Polish biotech **Urteste** partners with **Aurevia** to conduct a clinical trial evaluating its **Panuri test**, a device for detecting pancreatic cancer. The trial will take place across research sites in three European countries. Aurevia secures a **$3.4 million contract** to manage the study.
Urteste initiates a European multicenter clinical study for its **Panuri test**, a diagnostic tool. The trial will involve multiple sites across Europe to evaluate its performance and safety. The study marks a key step in advancing the test’s regulatory approval and potential market adoption.

Urteste develops early-stage cancer detection technology that measures enzyme activity in urine.